Research programme: metal-protein-attenuating compounds - Prana BiotechnologyAlternative Names: MPAC - Prana Biotechnologies; PBT 519; PBT-434; PBT3 series - Prana Biotechnologies; PBT4 series - Prana Biotechnologies
Latest Information Update: 08 Mar 2016
At a glance
- Originator Prana Biotechnology
- Class Quinazolinones
- Mechanism of Action Alpha-synuclein inhibitors; Iron chelating agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Alzheimer's disease; Brain cancer; Parkinson's disease; Parkinsonian disorders
- Research Neurodegenerative disorders